AU2006299028A1 - Imidazopyridine derivatives as A2B adenosine receptor antagonists - Google Patents

Imidazopyridine derivatives as A2B adenosine receptor antagonists Download PDF

Info

Publication number
AU2006299028A1
AU2006299028A1 AU2006299028A AU2006299028A AU2006299028A1 AU 2006299028 A1 AU2006299028 A1 AU 2006299028A1 AU 2006299028 A AU2006299028 A AU 2006299028A AU 2006299028 A AU2006299028 A AU 2006299028A AU 2006299028 A1 AU2006299028 A1 AU 2006299028A1
Authority
AU
Australia
Prior art keywords
pyridin
imidazo
pyridine
fluoropyridin
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006299028A
Other languages
English (en)
Inventor
Jose Aiguade Bosch
Aranzazu Cardus Figueras
Ines Carranco Moruno
Paul Robert Eastwood
Silvia Fonquerna Pou
Jacob Gonzalez Rodriguez
Sergio Paredes Aparicio
Bernat Vidal Juan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Laboratorios Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Almirall SA filed Critical Laboratorios Almirall SA
Publication of AU2006299028A1 publication Critical patent/AU2006299028A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006299028A 2005-10-06 2006-10-05 Imidazopyridine derivatives as A2B adenosine receptor antagonists Abandoned AU2006299028A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200502433A ES2274712B1 (es) 2005-10-06 2005-10-06 Nuevos derivados imidazopiridina.
ESP200502433 2005-10-06
PCT/EP2006/009620 WO2007039297A1 (en) 2005-10-06 2006-10-05 Imidazopyridine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
AU2006299028A1 true AU2006299028A1 (en) 2007-04-12

Family

ID=36295447

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006299028A Abandoned AU2006299028A1 (en) 2005-10-06 2006-10-05 Imidazopyridine derivatives as A2B adenosine receptor antagonists

Country Status (18)

Country Link
US (1) US7855202B2 (https=)
EP (1) EP1931666A1 (https=)
JP (1) JP2009510152A (https=)
KR (1) KR20080050475A (https=)
CN (1) CN101326181A (https=)
AR (1) AR055676A1 (https=)
AU (1) AU2006299028A1 (https=)
CA (1) CA2624879A1 (https=)
EC (1) ECSP088343A (https=)
ES (1) ES2274712B1 (https=)
IL (1) IL190336A0 (https=)
NO (1) NO20082121L (https=)
PE (1) PE20070706A1 (https=)
RU (1) RU2008117329A (https=)
TW (1) TW200800985A (https=)
UY (1) UY29836A1 (https=)
WO (1) WO2007039297A1 (https=)
ZA (1) ZA200802588B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2294066B9 (en) * 2008-04-28 2015-03-11 Janssen Pharmaceutica, N.V. Benzoimidazoles as prolyl hydroxylase inhibitors
WO2010133534A1 (en) * 2009-05-19 2010-11-25 Cellzome Limited Bicyclic amino substituted compounds as pi3k inhibitors
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
BR112012032766A2 (pt) 2010-06-30 2019-09-24 Gilead Sciences Inc uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
WO2012033149A1 (ja) * 2010-09-10 2012-03-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
KR101913619B1 (ko) * 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
US9273034B2 (en) 2011-10-25 2016-03-01 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
JP2015515472A (ja) 2012-04-06 2015-05-28 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
RU2644558C2 (ru) * 2012-06-19 2018-02-13 Сановьон Фармасьютикалз Инк. Гетероарильные соединения и способы их применения
US9650376B2 (en) 2013-03-15 2017-05-16 Knopp Biosciences Llc Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
US11435340B2 (en) 2014-06-09 2022-09-06 Biometry Inc. Low cost test strip and method to measure analyte
SI3572405T1 (sl) 2014-09-12 2023-12-29 Biohaven Therapeutics Ltd. Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7
ES2580702B1 (es) * 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
EP3487407B1 (en) 2016-07-19 2024-10-02 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
FI3562487T3 (fi) 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
US11312715B2 (en) 2017-09-28 2022-04-26 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Fused ring derivative as A2A receptor inhibitor
ES2992256T3 (es) * 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
CA3126224A1 (en) 2019-01-08 2020-07-16 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer
WO2021095805A1 (ja) * 2019-11-13 2021-05-20 日本新薬株式会社 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤
BR112022008571A2 (pt) 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309573D0 (en) * 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
KR0151816B1 (ko) * 1994-02-08 1998-10-15 강박광 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
ES2304797T3 (es) 1997-12-19 2008-10-16 Amgen Inc. Compuestos de piridina y piridazina sustituidos y su uso farmaceutico.
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
EP1208100B1 (en) 1999-08-31 2003-04-02 Vanderbilt University Selective antagonists of a2b adenosine receptors
CA2400206A1 (en) 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
JP4064671B2 (ja) 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
KR20070058022A (ko) 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물
JP4251868B2 (ja) * 2000-08-11 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−アミノピリジン化合物および医薬用途
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4122216B2 (ja) 2000-09-19 2008-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＧＳＫ−３βタンパク質の特徴づけおよびその使用方法
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DE60206756T2 (de) * 2001-06-29 2006-07-13 CV Therapeutics, Inc., Palo Alto Purin derivate als a2b adenosin rezeptor antagonisten
TWI330183B (https=) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
DK1444233T3 (da) 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
US20050043315A1 (en) 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
MXPA03008967A (es) 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
EA200500005A1 (ru) 2002-06-12 2005-06-30 Байоджен Айдек Ма Инк. Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина
US20040067955A1 (en) 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
KR20120032574A (ko) 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
DE60322748D1 (de) 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
ES2557310T3 (es) 2003-08-25 2016-01-25 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
CA2544193C (en) 2003-10-31 2012-03-27 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2303776B1 (es) 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

Also Published As

Publication number Publication date
ZA200802588B (en) 2009-09-30
AR055676A1 (es) 2007-08-29
WO2007039297A1 (en) 2007-04-12
ES2274712A1 (es) 2007-05-16
JP2009510152A (ja) 2009-03-12
RU2008117329A (ru) 2009-11-20
US7855202B2 (en) 2010-12-21
TW200800985A (en) 2008-01-01
UY29836A1 (es) 2007-04-30
US20080275038A1 (en) 2008-11-06
ES2274712B1 (es) 2008-03-01
IL190336A0 (en) 2009-09-22
KR20080050475A (ko) 2008-06-05
CN101326181A (zh) 2008-12-17
CA2624879A1 (en) 2007-04-12
PE20070706A1 (es) 2007-09-24
NO20082121L (no) 2008-07-07
EP1931666A1 (en) 2008-06-18
ECSP088343A (es) 2008-05-30

Similar Documents

Publication Publication Date Title
US7855202B2 (en) Imidazopyridine derivatives as A2B adenosine receptor antagonists
US20090023763A1 (en) Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists
ES2270715B1 (es) Nuevos derivados de pirazina.
AU2018267545B2 (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US7618964B2 (en) Benzamide derivatives, their manufacture and use as pharmaceutical agents
JP2016506368A (ja) ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物
JP2009528989A (ja) Ｔｌｒ７変調剤としての３−デアザプリン誘導体
EP2125804B1 (en) 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazo[4,5-b]pyridin-2-one derivatives useful as a2b adenosine receptor antagonists
CA2524622A1 (en) Substituted-1-phthalazinamines as vr-1 antagonists
CA2586265A1 (en) Nicotinamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors
AU2014372639A1 (en) Benzene sulfonamides as CCR9 inhibitors

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period